Webinar to discuss EMA's opinion on 9 June

The PREFER project is officially ending today, but our legacy continues! On 9 June at 16:00 CEST, we invite you to discuss the future impacts of the European Medicines Agency's (EMA) qualification opinion on our framework and points to consider for patient preference studies. The online event is open to everyone and free to attend! 

We have shared the PREFER framework and points to consider for method selection for a patient preference study with the European Medicines Agency (EMA) and the EUNetHTA network of health technology assessment bodies for scientific advice. That process included a public consultation where many of our stakeholders contributed. This month, the CHMP, EMA's committee responsible for human medicines, adopted a positive qualification opinion. To learn more about the CHMP positive opinion, we invite you to join us as we discuss key findings from the process and potential future implications.

The 1-hour online event will occur on 9 June 2022 at 16:00 CEST. 

Read qualification opinion





  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.


The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).